Genetics and genomics in pediatric septic shock

Critical Care Medicine

Volumn 40, Issue 5, 2012, Pages 1618-1626

  Wong, Hector R ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Children; expression profiling; genomics; polymorphism; sepsis

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; NEUTROPHIL COLLAGENASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ZINC;

ALLELE; ARTICLE; BLOOD CLOTTING; CHEMICAL MODIFICATION; DISEASE PREDISPOSITION; DNA SEQUENCE; ENZYME INHIBITION; EPIGENETICS; ESCHERICHIA COLI INFECTION; GENE DELETION; GENE EXPRESSION PROFILING; GENE INSERTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETICS; GENOMICS; HAPLOTYPE; HUMAN; IMMUNITY; INFLAMMATION; MENINGOCOCCEMIA; PRIORITY JOURNAL; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; STAPHYLOCOCCUS INFECTION; SUPPLEMENTATION;

CHILD; EPIGENOMICS; GENE EXPRESSION PROFILING; GENETIC MARKERS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; SHOCK, SEPTIC; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84860234453     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318246b546     Document Type: Article

References (166)

1. Odetola FO, Gebremariam A, Freed GL: Patient and hospital correlates of clinical outcomes and resource utilization in severe pediatric sepsis. Pediatrics 2007; 119:487-494
2. Markovitz BP, Goodman DM, Watson RS, et al: A retrospective cohort study of prognostic factors associated with outcome in pediatric severe sepsis: What is the role of steroids? Pediatr Crit Care Med 2005; 6:270-274
3. Watson RS, Carcillo JA, Linde-Zwirble WT, et al: The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695-701
4. Watson RS, Carcillo JA: Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med 2005; 6:S3-S5
5. Czaja AS, Zimmerman JJ, Nathens AB: Readmission and late mortality after pediatric severe sepsis. Pediatrics 2009; 123:849-857
6. Cornell TT, Wynn J, Shanley TP, et al: Mechanisms and regulation of the geneexpression response to sepsis. Pediatrics 2010; 125:1248-1258
7. Wong HR: Pediatric septic shock treatment: New clues from genomic profiling. Pharmacogenomics 2007; 8:1287-1290
8. Shanley TP, Wong HR: Molecular genetics in the pediatric intensive care unit. Crit Care Clin 2003; 19:577-594
9. Sorensen TI, Nielsen GG, Andersen PK, et al: Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318:727-732
10. Manolio TA, Collins FS: The HapMap and genome-wide association studies in diagnosis and therapy. Annu Rev Med 2009; 60:443-456
11. Dahmer MK, Randolph A, Vitali S, et al: Genetic polymorphisms in sepsis. Pediatr Crit Care Med 2005; 6:S61-S73
12. Liangos O, Jaber BL: Multiple organ dysfunction syndrome in children with sepsis: Role of genetic factors. Semin Nephrol 2008; 28:499-509
13. Namath A, Patterson AJ: Genetic polymorphisms in sepsis. Crit Care Clin 2009; 25:835-856, x
14. Sutherland AM, Walley KR: Bench-to-bedside review: Association of genetic variation with sepsis. Crit Care 2009; 13:210
15. Yende S, Kammerer CM, Angus DC: Genetics and proteomics: Deciphering gene association studies in critical illness. Crit Care 2006; 10:227
16. Freely associating. Nat Genet 1999; 22:1-2
17. Hobson MJ, Wong HR: Genetic association research: Understanding its challenges and limitations. Pediatr Crit Care Med 2010; 11:762-763
18. Stalets E, Wong HR: Critically associating. Crit Care Med 2009; 37:1492-1493
19. Clark MF, Baudouin SV: A systematic review of the quality of genetic association studies in human sepsis. Intensive Care Med 2006; 32:1706-1712
20. Little J, Higgins JP, Ioannidis JP, et al: STrengthening the REporting of Genetic Association Studies (STREGA): An extension of the STROBE statement. PLoS Med 2009; 6(2):e22
21. Aso Y: Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 2007; 12:2957-2966
22. Pannekoek H, Veerman H, Lambers H, et al: Endothelial plasminogen activator inhibitor (PAI): A new member of the Serpin gene family. EMBO J 1986; 5:2539-2544
23. Dawson SJ, Wiman B, Hamsten A, et al: The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268:10739-10745
24. Petaja J: Inflammation and coagulation. An overview. Thromb Res 2011; 127:S34-S37
25. Powars DR, Rogers ZR, Patch MJ, et al: Purpura fulminans in meningococcemia: Association with acquired deficiencies of proteins C and S. N Engl J Med 1987; 317:571-572
26. Hazelzet JA, Risseeuw-Appel IM, Kornelisse RF, et al: Age-related differences in outcome and severity of DIC in children with septic shock and purpura. Thromb Haemost 1996; 76:932-938
27. Machado FR, Cesar MS: Sepsis, coagulation and anticoagulants. Endocr Metab Immune Disord Drug Targets 2010; 10:204-213
28. Hermans PW, Hibberd ML, Booy R, et al: 4G/5G promoter polymorphism in the plasminogenactivator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354:556-560
29. Geishofer G, Binder A, Muller M, et al: 4G/5G promoter polymorphism in the plasminogenactivator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr 2005; 164:486-490
30. Haralambous E, Hibberd ML, Hermans PW, et al: Role of functional plasminogen-activatorinhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit Care Med 2003; 31:2788-2793
31. Westendorp RG, Hottenga JJ, Slagboom PE: Variation in plasminogen-activatorinhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999; 354:561-563
32. Brouwer MC, Read RC, van de Beek D: Host genetics and outcome in meningococcal disease: A systematic review and metaanalysis. Lancet Infect Dis 2010; 10:262-274
33. Nadel S, Goldstein B, Williams MD, et al: Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet 2007; 369:836-843
34. Casanova JL, Abel L, Quintana-Murci L: Human TLRs and IL-1Rs in host defense: Natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 2011; 29:447-491
35. Lorenz E, Mira JP, Cornish KL, et al: A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000; 68:6398-6401
36. Moore CE, Segal S, Berendt AR, et al: Lack of association between Toll-like receptor 2 polymorphisms and susceptibility to severe disease caused by Staphylococcus aureus. Clin Diagn Lab Immunol 2004; 11:1194-1197
37. Von Aulock S, Schroder NW, Traub S, et al: Heterozygous toll-like receptor 2 polymorphism does not affect lipoteichoic acid-induced chemokine and inflammatory responses. Infect Immun 2004; 72:1828-1831
38. Kutukculer N, Yeniay BS, Aksu G, et al: Arg753Gln polymorphism of the human toll-like receptor-2 gene in children with recurrent febrile infections. Biochem Genet 2007; 45:507-514
39. Tabel Y, Berdeli A, Mir S: Association of TLR2 gene Arg753Gln polymorphism with urinary tract infection in children. Int J Immunogenet 2007; 34:399-405
40. Krediet TG, Wiertsema SP, Vossers MJ, et al: Toll-like receptor 2 polymorphism is associated with preterm birth. Pediatr Res 2007; 62:474-476
41. Berdeli A, Celik HA, Ozyurek R, et al: TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children. J Mol Med (Berl) 2005; 83:535-541
42. Abu-Maziad A, Schaa K, Bell EF, et al: Role of polymorphic variants as genetic modulators of infection in neonatal sepsis. Pediatr Res 2010; 68:323-329
43. Sutherland AM, Walley KR, Russell JA: Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med 2005; 33:638-644
44. Beutler B, Poltorak A: The sole gateway to endotoxin response: How LPS was identified as Tlr4, and its role in innate immunity. Drug Metab Dispos 2001; 29:474-478
45. Qureshi ST, Lariviere L, Leveque G, et al: Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med 1999; 189:615-625
46. Poltorak A, He X, Smirnova I, et al: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998; 282:2085-2088
47. Hoshino K, Takeuchi O, Kawai T, et al: Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product. J Immunol 1999; 162:3749-3752
48. Arbour NC, Lorenz E, Schutte BC, et al: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25:187-191
49. Michel O, LeVan TD, Stern D, et al: Systemic responsiveness to lipopolysaccharide and polymorphisms in the toll-like receptor 4 gene in human beings. J Allergy Clin Immunol 2003; 112:923-929
50. Douville RN, Lissitsyn Y, Hirschfeld AF, et al: TLR4 Asp299Gly and Thr399Ile polymorphisms: No impact on human immune responsiveness to LPS or respiratory syncytial virus. PLoS One 2010; 5:e12087
51. Lorenz E, Mira JP, Frees KL, et al: Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002; 162:1028-1032
52. Agnese DM, Calvano JE, Hahm SJ, et al: Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002; 186:1522-1525
53. Faber J, Henninger N, Finn A, et al: A tolllike receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease. Acta Paediatr 2009; 98:548-552
54. Read RC, Pullin J, Gregory S, et al: A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 2001; 184:640-642
55. Allen A, Obaro S, Bojang K, et al: Variation in Toll-like receptor 4 and susceptibility to group A meningococcal meningitis in Gambian children. Pediatr Infect Dis J 2003; 22:1018-1019
56. Smirnova I, Mann N, Dols A, et al: Assay of locus-specific genetic load implicates rare Tolllike receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci USA 2003; 100:6075-6080
57. Mockenhaupt FP, Cramer JP, Hamann L, et al: Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria. J Commun Dis 2006; 38:230-245
58. Khor CC, Chapman SJ, Vannberg FO, et al: A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39:523-528
59. Ferwerda B, Alonso S, Banahan K, et al: Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci USA 2009; 106:10272-10277
60. Kumpf O, Giamarellos-Bourboulis EJ, Koch A, et al: Influence of genetic variations in TLR4 and TIRAP/Mal on the course of sepsis and pneumonia and cytokine release: An observational study in three cohorts. Crit Care 2010; 14:R103
61. Ladhani SN, Davila S, Hibberd ML, et al: Association between single-nucleotide polymorphisms in Mal/TIRAP and interleukin 10 genes and susceptibility to invasive haemophilus influenzae serotype b infection in immunized children. Clin Infect Dis 2010; 51:761-767
62. Beutler B: TNF, immunity and inflammatory disease: Lessons of the past decade. J Investig Med 1995; 43:227-235
63. Beutler B, Cerami A: Tumor necrosis, cachexia, shock, and inflammation: A common mediator. Annu Rev Biochem 1988; 57:505-518
64. Lorente JA, Marshall JC: Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 2005; 24:107-119
65. Smith AJ, Humphries SE: Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009; 20:43-59
66. Wilson AG, de Vries N, Pociot F, et al: An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177:557-560
67. Wilson AG, Symons JA, McDowell TL, et al: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94:3195-3199
68. Kroeger KM, Carville KS, Abraham LJ: The-308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997; 34:391-399
69. Louis E, Franchimont D, Piron A, et al: Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113:401-406
70. Mira JP, Cariou A, Grall F, et al: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999; 282:561-568
71. Stuber F, Udalova IA, Book M, et al: 308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1995; 46:42-50
72. Read RC, Teare DM, Pridmore AC, et al: The tumor necrosis factor polymorphism TNF (-308) is associated with susceptibility to meningococcal sepsis, but not with lethality. Crit Care Med 2009; 37:1237-1243
73. Teuffel O, Ethier MC, Beyene J, et al: Association between tumor necrosis factoralpha promoter-308 A/G polymorphism and susceptibility to sepsis and sepsis mortality: A systematic review and meta-analysis. Crit Care Med 2010; 38:276-282
74. Nadel S, Newport MJ, Booy R, et al: Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996; 174:878-880
75. Sipahi T, Pocan H, Akar N: Effect of various genetic polymorphisms on the incidence and outcome of severe sepsis. Clin Appl Thromb Hemost 2006; 12:47-54
76. Stuber F, Petersen M, Bokelmann F, et al: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24:381-384
77. McArthur JA, Zhang Q, Quasney MW: Association between the A/A genotype at the lymphotoxin-alpha+250 site and increased mortality in children with positive blood cultures. Pediatr Crit Care Med 2002; 3:341-344
78. Christie JD: Microarrays. Crit Care Med 2005; 33:S449-S452
79. Gershon D: Microarray technology: An array of opportunities. Nature 2002; 416:885-891
80. Calvano SE, Xiao W, Richards DR, et al: A network-based analysis of systemic inflammation in humans. Nature 2005; 437:1032-1037
81. Johnson SB, Lissauer M, Bochicchio GV, et al: Gene expression profiles differentiate between sterile SIRS and early sepsis. Ann Surg 2007; 245:611-621
82. Pachot A, Lepape A, Vey S, et al: Systemic transcriptional analysis in survivor and nonsurvivor septic shock patients: A preliminary study. Immunol Lett 2006; 106:63-71
83. Payen D, Lukaszewicz AC, Belikova I, et al: Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med 2008; 34:1371-1376
84. Prabhakar U, Conway TM, Murdock P, et al: Correlation of protein and gene expression profiles of inflammatory proteins after endotoxin challenge in human subjects. DNA Cell Biol 2005; 24:410-431
85. Prucha M, Ruryk A, Boriss H, et al: Expression profiling: Toward an application in sepsis diagnostics. Shock 2004; 22:29-33
86. Suffredini AF, Fromm RE, Parker MM, et al: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321:280-287
87. Talwar S, Munson PJ, Barb J, et al: Gene expression profiles of peripheral blood leukocytes after endotoxin challenge in humans. Physiol Genomics 2006; 25:203-215
88. Tang BM, Huang SJ, McLean AS: Genomewide transcription profiling of human sepsis: A systematic review. Crit Care 2010; 14:R237
89. Tang BM, McLean AS, Dawes IW, et al: Geneexpression profiling of gram-positive and gram-negative sepsis in critically ill patients. Crit Care Med 2008; 36:1125-1128
90. Tang BM, McLean AS, Dawes IW, et al: The use of gene-expression profiling to identify candidate genes in human sepsis. Am J Respir Crit Care Med 2007; 176:676-684
91. Tang BM, McLean AS, Dawes IW, et al: Geneexpression profiling of peripheral blood mononuclear cells in sepsis. Crit Care Med 2009; 37:882-888
92. Pathan N, Hemingway CA, Alizadeh AA, et al: Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 2004; 363:203-209
93. Cvijanovich N, Shanley TP, Lin R, et al: Validating the genomic signature of pediatric septic shock. Physiol Genomics 2008; 34:127-134
94. Shanley TP, Cvijanovich N, Lin R, et al: Genome-level longitudinal expression of signaling pathways and gene networks in pediatric septic shock. Mol Med 2007; 13:495-508
95. Wong HR, Cvijanovich N, Allen GL, et al: Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Crit Care Med 2009; 37:1558-1566
96. Wong HR, Cvijanovich N, Lin R, et al: Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med 2009; 7:34
97. Wong HR, Shanley TP, Sakthivel B, et al: Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol Genomics 2007; 30:146-155
98. Rink L, Haase H: Zinc homeostasis and immunity. Trends Immunol 2007; 28:1-4
99. Cvijanovich NZ, King JC, Flori HR, et al: Zinc homeostasis in pediatric critical illness. Pediatr Crit Care Med 2009; 10:29-34
100. Heyland DK, Jones N, Cvijanovich NZ, et al: Zinc supplementation in critically ill patients: A key pharmaconutrient? JPEN J Parenter Enteral Nutr 2008; 32:509-519
101. Weitzel LR, Mayles WJ, Sandoval PA, et al: Effects of pharmaconutrients on cellular dysfunction and the microcirculation in critical illness. Curr Opin Anaesthesiol 2009; 22:177-183
102. Bao S, Liu MJ, Lee B, et al: Zinc modulates the innate immune response in vivo to polymicrobial sepsis through regulation of NF-kappaB. Am J Physiol Lung Cell Mol Physiol 2010; 298:L744-L754
103. Knoell DL, Julian MW, Bao S, et al: Zinc deficiency increases organ damage and mortality in a murine model of polymicrobial sepsis. Crit Care Med 2009; 37:1380-1388
104. Besecker BY, Exline MC, Hollyfield J, et al: A comparison of zinc metabolism, inflammation, and disease severity in critically ill infected and noninfected adults early after intensive care unit admission. Am J Clin Nutr 2011; 93:1356-1364
105. Knoell DL, Liu MJ: Impact of zinc metabolism on innate immune function in the setting of sepsis. Int J Vitam Nutr Res 2010; 80:271-277
106. Carcillo J, Holubkov R, Dean JM, et al: Rationale and design of the pediatric critical illness stress-induced immune suppression (CRISIS) prevention trial. JPEN J Parenter Enteral Nutr 2009; 33:368-374
107. Huang DT, Ochoa JB: Nutrition trials in critical illness: Bigger, faster, stronger. JPEN J Parenter Enteral Nutr 2010; 34:608-609
108. Neu J: Use of nutrition to prevent stressinduced immunosuppression in the pediatric intensive care unit: A clinical trials minefield. JPEN J Parenter Enteral Nutr 2009; 33:440-441
109. Wong HR, Freishtat RJ, Monaco M, et al: Leukocyte subset-derived genomewide expression profiles in pediatric septic shock. Pediatr Crit Care Med 2010; 11:349-355
110. Wynn JL, Cvijanovich NZ, Allen GL, et al: The influence of developmental age on the early transcriptomic response of children with septic shock. Mol Med 2011; 17:1146-1156
111. Solan PD, Dunsmore KE, Denenberg AG, et al: A novel role for matrix metalloproteinase-8 in sepsis. Crit Care Med 2012; 40:379-387
112. Van Lint P, Libert C: Matrix metalloproteinase-8: Cleavage can be decisive. Cytokine Growth Factor Rev 2006; 17:217-223
113. Vanlaere I, Libert C: Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock. Clin Microbiol Rev 2009; 22:224-239, Table of Contents
114. Bouchon A, Facchetti F, Weigand MA, et al: TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001; 410:1103-1107
115. Galetto-Lacour A, Gervaix A: Identifying severe bacterial infection in children with fever without source. Expert Rev Anti Infect Ther 2010; 8:1231-1237
116. Ramilo O, Allman W, Chung W, et al: Gene expression patterns in blood leukocytes discriminate patients with acute infections. Blood 2007; 109:2066-2077
117. Allantaz F, Chaussabel D, Stichweh D, et al: Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med 2007; 204:2131-2144
118. Kaplan JM, Wong HR: Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med 2011; 12:165-173
119. Marshall JC: Sepsis: Rethinking the approach to clinical research. J Leukoc Biol 2008; 83:471-482
120. Marshall JC, Vincent JL, Fink MP, et al: Measures, markers, and mediators: Toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 2003; 31:1560-1567
121. Wong HR, Cvijanovich N, Wheeler DS, et al: Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med 2008; 178:276-282
122. Calfee CS, Thompson BT, Parsons PE, et al: Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock. Crit Care Med 2010; 38:1436-1441
123. Nowak JE, Wheeler DS, Harmon KK, et al: Admission chemokine (C-C motif) ligand 4 levels predict survival in pediatric septic shock. Pediatr Crit Care Med 2010; 11:213-216
124. Standage SW, Wong HR: Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther 2011; 9:71-79
125. Wong HR, Wheeler DS, Tegtmeyer K, et al: Toward a clinically feasible gene expressionbased subclassification strategy for septic shock: Proof of concept. Crit Care Med 2010; 38:1955-1961
126. Eichler GS, Huang S, Ingber DE: Gene Expression Dynamics Inspector (GEDI): For integrative analysis of expression profiles. Bioinformatics 2003; 19:2321-2322
127. Guo Y, Eichler GS, Feng Y, et al: Towards a holistic, yet gene-centered analysis of gene expression profiles: A case study of human lung cancers. J Biomed Biotechnol 2006; 2006:69141
128. Wong HR, Cvijanovich NZ, Allen GL, et al: Validation of a gene expression-based subclassification strategy for pediatric septic shock. Crit Care Med 2011; 39:2511-2517
129. Delcuve GP, Rastegar M, Davie JR: Epigenetic control. J Cell Physiol 2009; 219:243-250
130. Carson WF, Cavassani KA, Dou Y, et al: Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics 2011; 6:273-283
131. Chan C, Li L, McCall CE, et al: Endotoxin tolerance disrupts chromatin remodeling and NF-kappaB transactivation at the IL-1beta promoter. J Immunol 2005; 175:461-468
132. El Gazzar M, Yoza BK, Chen X, et al: Chromatin-specific remodeling by HMGB1 and linker histone H1 silences proinflammatory genes during endotoxin tolerance. Mol Cell Biol 2009; 29:1959-1971
133. El Gazzar M, Yoza BK, Chen X, et al: G9a and HP1 couple histone and DNA methylation to TNFalpha transcription silencing during endotoxin tolerance. J Biol Chem 2008; 283:32198-32208
134. Foster SL, Hargreaves DC, Medzhitov R: Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007; 447:972-978
135. Brogdon JL, Xu Y, Szabo SJ, et al: Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007; 109:1123-1130
136. Tsaprouni LG, Ito K, Adcock IM, et al: Suppression of lipopolysaccharideand tumour necrosis factor-alphainduced interleukin (IL)-8 expression by glucocorticoids involves changes in IL-8 promoter acetylation. Clin Exp Immunol 2007; 150:151-157
137. McCall CE, Yoza B, Liu T, et al: Gene-specific epigenetic regulation in serious infections with systemic inflammation. J Innate Immun 2010; 2:395-405
138. Ishii M, Wen H, Corsa CA, et al: Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 2009; 114:3244-3254
139. Wen H, Dou Y, Hogaboam CM, et al: Epigenetic regulation of dendritic cellderived interleukin-12 facilitates immunosuppression after a severe innate immune response. Blood 2008; 111:1797-1804
140. Wen H, Schaller MA, Dou Y, et al: Dendritic cells at the interface of innate and acquired immunity: The role for epigenetic changes. J Leukoc Biol 2008; 83:439-446
141. Quartin AA, Schein RM, Kett DH, et al: Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 1997; 277:1058-1063
142. Winters BD, Eberlein M, Leung J, et al: Long-term mortality and quality of life in sepsis: A systematic review. Crit Care Med 2010; 38:1276-1283
143. Read RC, Cannings C, Naylor SC, et al: Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann Intern Med 2003; 138:534-541
144. Endler G, Marculescu R, Starkl P, et al: Polymorphisms in the interleukin-1 gene cluster in children and young adults with systemic meningococcemia. Clin Chem 2006; 52:511-514
145. Michalek J, Svetlikova P, Fedora M, et al: Interleukin-6 gene variants and the risk of sepsis development in children. Hum Immunol 2007; 68:756-760
146. Lehrnbecher T, Bernig T, Hanisch M, et al: Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia. Leukemia 2005; 19:1745-1750
147. Artifoni L, Negrisolo S, Montini G, et al: Interleukin-8 and CXCR1 receptor functional polymorphisms and susceptibility to acute pyelonephritis. J Urol 2007; 177:1102-1106
148. Binder A, Endler G, Rieger S, et al: Protein C promoter polymorphisms associate with sepsis in children with systemic meningococcemia. Hum Genet 2007; 122:183-190
149. Bredius RG, Derkx BH, Fijen CA, et al: Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis 1994; 170:848-853
150. Van Sorge NM, van der Pol WL, van de Winkel JG: FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003; 61:189-202
151. Domingo P, Muniz-Diaz E, Baraldes MA, et al: Associations between Fc gamma receptor IIA polymorphisms and the risk and prognosis of meningococcal disease. Am J Med 2002; 112:19-25
152. Platonov AE, Shipulin GA, Vershinina IV, et al: Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 1998; 27:746-750
153. Platonov AE, Kuijper EJ, Vershinina IV, et al: Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement component-deficient individuals. Clin Exp Immunol 1998; 111:97-101
154. Hibberd ML, Sumiya M, Summerfield JA, et al: Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 1999; 353:1049-1053
155. Summerfield JA, Sumiya M, Levin M, et al: Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997; 314:1229-1232
156. Koch A, Melbye M, Sorensen P, et al: Acute respiratory tract infections and mannosebinding lectin insufficiency during early childhood. JAMA 2001; 285:1316-1321
157. Michalek J, Svetlikova P, Fedora M, et al: Bactericidal permeability increasing protein gene variants in children with sepsis. Intensive Care Med 2007; 33:2158-2164
158. El Saleeby CM, Li R, Somes GW, et al: Surfactant protein A2 polymorphisms and disease severity in a respiratory syncytial virus-infected population. J Pediatr 2010; 156:409-414
159. Dahmer MK, O'cain P, Patwari PP, et al: The influence of genetic variation in surfactant protein B on severe lung injury in African American children. Crit Care Med 2011; 39:1138-1144
160. Agbeko RS, Fidler KJ, Allen ML, et al: Genetic variability in complement activation modulates the systemic inflammatory response syndrome in children. Pediatr Crit Care Med 2010; 11:561-567
161. Haralambous E, Dolly SO, Hibberd ML, et al: Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand J Infect Dis 2006; 38:764-771
162. Davila S, Wright VJ, Khor CC, et al: Genomewide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease. Nat Genet 2010; 42:772-776
163. Harding D, Baines PB, Brull D, et al: Severity of meningococcal disease in children and the angiotensin-converting enzyme insertion/deletion polymorphism. Am J Respir Crit Care Med 2002; 165:1103-1106
164. Cogulu O, Onay H, Uzunkaya D, et al: Role of angiotensin-converting enzyme gene polymorphisms in children with sepsis and septic shock. Pediatr Int 2008; 50:477-480
165. Tekin D, Dalgic N, Kayaalti Z, et al: Importance of NOD2/CARD15 gene variants for susceptibility to and outcome of sepsis in Turkish children. Pediatr Crit Care Med 2011 Mar 31. [Epub ahead of print]
166. Khor CC, Vannberg FO, Chapman SJ, et al: CISH and susceptibility to infectious diseases. N Engl J Med 2010; 362:2092-2101